3-(3-bromophenyl)-N,N-dimethylpropanamide | 1340177-32-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-bromophenyl)-N,N-dimethylpropanamide
• CAS: 1340177-32-3
• 化学式: C₁₁H₁₄BrNO
• mdl: MFCD20355161
• 分子量: 256.142
• InChiKey: BDCFZIWQRLXXEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3-bromophenyl)-N,N-dimethylpropanamide 在 吡啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 tetraphosphorus decasulfide 、 硼烷四氢呋喃络合物 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 7.34h， 生成 9-chloro-2-({3-[3-(dimethylamino)propyl]phenyl}amino)-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepine-6-thione
  参考文献：
  名称：

  Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)

  摘要：

  This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.

  DOI：

  10.1021/jm2011172
• 作为产物：
  描述：

  3-(3-溴苯基)丙酸 、 盐酸二甲胺 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 15.17h， 以88%的产率得到3-(3-bromophenyl)-N,N-dimethylpropanamide
  参考文献：
  名称：

  Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)

  摘要：

  This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.

  DOI：

  10.1021/jm2011172

文献信息

• [EN] NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA<br/>[FR] NOUVEAUX COMPOSES 2-AMINO-IMIDAZOLE-4-ONE ET LEUR UTILISATION DANS LA FABRICATION D'UN MEDICAMENT DESTINE A ETRE UTILISE DANS LE TRAITEMENT D'UNE DEFICIENCE COGNITIVE, LA MALADIE D'ALZHEIMER, LE NEURODEGENERESCENCE ET LA DEMENCE
  申请人：ASTRAZENECA AB

  公开号：WO2007058601A1

  公开（公告）日：2007-05-24

  [EN] This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
  [FR] L'invention concerne de nouveaux composés présentant de formule structurelle (I) et leurs sels pharmaceutiquement acceptables, leurs compositions et leurs procédés d'utilisation. Les nouveaux composés de l'invention sont utilisés dans le traitement ou la prophylaxie d'une déficience cognitive, de la maladie d'Alzheimer, de la neurodégénerescence et de la démence.
• Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)
  作者：Matthew O. Duffey、Tricia J. Vos、Ruth Adams、Jennifer Alley、Justin Anthony、Cynthia Barrett、Indu Bharathan、Douglas Bowman、Nancy J. Bump、Ryan Chau、Courtney Cullis、Denise L. Driscoll、Amy Elder、Nancy Forsyth、Jonathan Frazer、Jianping Guo、Luyi Guo、Marc L. Hyer、David Janowick、Bheemashankar Kulkarni、Su-Jen Lai、Kerri Lasky、Gang Li、Jing Li、Debra Liao、Jeremy Little、Bo Peng、Mark G. Qian、Dominic J. Reynolds、Mansoureh Rezaei、Margaret Porter Scott、Todd B. Sells、Vaishali Shinde、Qiuju Judy Shi、Michael D. Sintchak、Francois Soucy、Kevin T. Sprott、Stephen G. Stroud、Michelle Nestor、Irache Visiers、Gabriel Weatherhead、Yingchun Ye、Natalie D’Amore

  DOI：10.1021/jm2011172

  日期：2012.1.12

  This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.